Eisai taps SFJ to speed lenvatinib to market
This article was originally published in Scrip
Executive Summary
Eisai has linked with the US/Japan drug development venture SFJ Pharmaceuticals to speed up the development of its pipeline anticancer molecule lenvatinib (E7080) for its lead indication of thyroid cancer.